Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/27548| Title: | Pazopanib-Induced Reversible Left Ventricular Systolic Dysfunction |
| Authors: | Roongsangmanoon W. Wattanawinitchai K. Charonpongsuntorn C. Chonmaitree P. Wongsoasup A. Rattanajaruskul N. Angkananard T. |
| Keywords: | bisoprolol furosemide hydralazine isosorbide dinitrate losartan pazopanib protein tyrosine kinase inhibitor sunitinib troponin valsartan aged |
| Issue Date: | 2022 |
| Abstract: | Pazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. The authors describe a patient with advanced renal cell carcinoma who developed severe hypertension and severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon treatment interruption. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND |
| URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123318091&doi=10.35755%2fjmedassocthai.2022.S01.00030&partnerID=40&md5=0dc61225497cf3b9c8c93a9208cc471c https://ir.swu.ac.th/jspui/handle/123456789/27548 |
| ISSN: | 1252208 |
| Appears in Collections: | Scopus 2022 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.